🇺🇸 FDA
Patent

US 11384154

Targeted chimeric proteins and uses thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11384154 (Targeted chimeric proteins and uses thereof) held by Orionis Biosciences, Inc expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Orionis Biosciences, Inc
Grant date
Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K2039/507, A61P, A61P1/16